All New issues

Alzai Health Corp.

Company Description

Alzai Health Corp. is a machine learning and artificial intelligence driven, non-invasive alzheimer’s disease (“AD”)/Alzheimer’s disease related dementia (“ADRD”) risk screening solution that uses low-cost, pre-existing biomarker data. AD/ADRD is defined as the clinical syndrome of AD, with or without vascular pathology per brain imaging but without the prior diagnosis of a stroke. AD/ADRD in this context does not include other forms of dementia. Alzai provides risk stratification, assisting in the process of early detection of AD/ADRD with the goal of improving patient treatment and outcomes. Alzai leverages ubiquitous data from demographics and blood panels present in nearly every adult medical record.

Proceeds

The net proceed of the offering will be used for research & development, sales & marketing, general working capital and listing fees, including legal.

---

Performance

	1 day	1 week	1 month	6 months	Inception
Recent Performance	-8.00 %	-9.80 %	-37.84 %		-42.50 %
Post IPO Performance	5.00 %	20.00 %

---

The content of this page is transmitted strictly for informational purposes. Investments must be selected in accordance with the investor's respective objectives. Desjardins Online Brokerage does not issue any recommendations or endorsements concerning any particular product, its potential value or appropriateness, or any specific strategy. It is highly recommended to read the prospectus before making any type of investment.